Business Context and Reporting Period
Company: Protagonist Therapeutics, Inc. (PTGX)
Filing Type: Form 8-K (Current Report)
Date of Report: September 17, 2021
Reporting Period: Event-based report regarding a specific regulatory occurrence on September 17, 2021.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a specific corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The primary material change reported is the placement of a clinical hold by the U.S. Food and Drug Administration (FDA) on the Company's clinical studies for its investigational product candidate, rusfertide.
Outlook, Risks, and Management Commentary
- Regulatory Action: The FDA has placed a clinical hold on the rusfertide development program.
- Reason for Hold: The hold relates to four cases of cancer observed across all rusfertide clinical trials to date.
- Company Assessment: Management states the four cases involve distinct forms of cancer and were assessed as unrelated to rusfertide, attributed instead to preexisting conditions or natural disease progression.
- Response: The Company has begun providing the FDA with requested information, including additional details regarding the cancer cases.
- Legal Disclaimer: The information in this Item 8.01 and the attached press release is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the status of the FDA clinical hold on rusfertide and any subsequent communications from the FDA.
- Review the attached press release (Exhibit 99.1) for detailed context on the clinical hold.
- Monitor future filings for updates on the resolution of the clinical hold and the impact on the development timeline.
- Assess the potential impact of the clinical hold on the Company's cash burn rate and future financing needs, as this filing does not provide current liquidity data.